Browsing Category

62660 posts
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ — Jacobin Pharma…
EXHIBITORS AND BUYERS UPBEAT AT MALAYSIAN INTERNATIONAL FURNITURE FAIR 2024

EXHIBITORS AND BUYERS UPBEAT AT MALAYSIAN INTERNATIONAL FURNITURE FAIR 2024

More international buyers and orders sealed KUALA LUMPUR, Malaysia, April 9, 2024…
Iridium Signs Five-Year Contract with L3Harris to Protect FAA Critical Infrastructure

Iridium Signs Five-Year Contract with L3Harris to Protect FAA Critical Infrastructure

Latest deployment of Iridium STL will provide a resilient timing sync service…
DFI Elevates Electric Vehicle Charging Experience at Embedded World 2024

DFI Elevates Electric Vehicle Charging Experience at Embedded World 2024

DFI to showcase the latest embedded solution powered by Intel TAIPEI, April…
Altair Wins 2024 Google Cloud North America Partner of the Year Award for Diversity, Equity, and Inclusion

Altair Wins 2024 Google Cloud North America Partner of the Year Award for Diversity, Equity, and Inclusion

Award recognizes Google Cloud partner that best prioritized DEI initiatives to transform…
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ — GenFleet Therapeutics, a…
GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ — GenFleet Therapeutics, a…
LyondellBasell demonstrates progress toward industry leadership in 2023 sustainability report

LyondellBasell demonstrates progress toward industry leadership in 2023 sustainability report

HOUSTON and ROTTERDAM, Netherlands, April 9, 2024 /PRNewswire/ — LyondellBasell (NYSE: LYB)…